209 related articles for article (PubMed ID: 29514360)
1. Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kishi T; Matsui Y; Matsuda Y; Katsuki A; Hori H; Yanagimoto H; Sanada K; Morita K; Yoshimura R; Shoji Y; Hagi K; Iwata N
Pharmacopsychiatry; 2019 Feb; 52(2):52-62. PubMed ID: 29514360
[TBL] [Abstract][Full Text] [Related]
2. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials.
Kishi T; Matsuda Y; Nakamura H; Iwata N
J Psychiatr Res; 2013 Feb; 47(2):149-54. PubMed ID: 23131856
[TBL] [Abstract][Full Text] [Related]
3. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
4. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Kishi T; Matsuda Y; Iwata N
PLoS One; 2014; 9(2):e88049. PubMed ID: 24505373
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole for schizophrenia.
El-Sayeh HG; Morganti C
Cochrane Database Syst Rev; 2004; (2):CD004578. PubMed ID: 15106256
[TBL] [Abstract][Full Text] [Related]
7. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.
Kishi T; Ikuta T; Sakuma K; Okuya M; Iwata N
J Psychiatr Res; 2021 Jun; 138():444-452. PubMed ID: 33964682
[TBL] [Abstract][Full Text] [Related]
9. Blonanserin: a review of its use in the management of schizophrenia.
Deeks ED; Keating GM
CNS Drugs; 2010 Jan; 24(1):65-84. PubMed ID: 20030420
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole versus typicals for schizophrenia.
Bhattacharjee J; El-Sayeh HG
Cochrane Database Syst Rev; 2008 Jan; (1):CD006617. PubMed ID: 18254107
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
Garcia E; Robert M; Peris F; Nakamura H; Sato N; Terazawa Y
CNS Drugs; 2009; 23(7):615-25. PubMed ID: 19552488
[TBL] [Abstract][Full Text] [Related]
12. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
Harvey PD; Nakamura H; Miura S
Neuropsychopharmacol Rep; 2020 Mar; 40(1):63-72. PubMed ID: 31788985
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
14. New generation antipsychotics for first episode schizophrenia.
Rummel C; Hamann J; Kissling W; Leucht S
Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012
[TBL] [Abstract][Full Text] [Related]
15. Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan.
Kishi T; Yoshimura R; Matsuda Y; Sakuma K; Iwata N
Pharmacopsychiatry; 2020 Apr; 53(3):122-132. PubMed ID: 32000271
[TBL] [Abstract][Full Text] [Related]
16. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials.
Zheng W; Xiang YT; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Correll CU
Acta Psychiatr Scand; 2016 Nov; 134(5):385-398. PubMed ID: 27585549
[TBL] [Abstract][Full Text] [Related]
18. Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
Harvey PD; Nakamura H; Murasaki M
Neuropsychopharmacol Rep; 2019 Sep; 39(3):173-182. PubMed ID: 31041855
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.
Iwata N; Ishigooka J; Kim WH; Yoon BH; Lin SK; Sulaiman AH; Cosca R; Wang L; Suchkov Y; Agarkov A; Watabe K; Matsui T; Sato T; Inoue Y; Higuchi T; Correll CU; Kane JM
Schizophr Res; 2020 Jan; 215():408-415. PubMed ID: 31471246
[TBL] [Abstract][Full Text] [Related]
20. Paliperidone for schizophrenia.
Nussbaum A; Stroup TS
Cochrane Database Syst Rev; 2008 Apr; (2):CD006369. PubMed ID: 18425951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
